Abstract:Targeted protein degradation (TPD) technology has gradually become widespread in the past 20 years, which greatly boosts the development of disease treatment. Contrary to small inhibitors that act on protein kinases, transcription factors, ion channels, and other targets they can bind to, targeted protein degraders could target "undruggable targets" and overcome drug resistance through ubiquitin–proteasome pathway (UPP) and lysosome pathway. Nowadays, some bivalent degraders such as proteolysis-targeting chimeras (PROTACs) have aroused great interest in drug discovery, and some of them have successfully advanced into clinical trials. In this review, to better understand the mechanism of degraders, we elucidate the targeted protein degraders according to their action process, relying on the ubiquitin–proteasome system or lysosome pathway. Then, we briefly summarize the study of PROTACs employing different E3 ligases. Subsequently, the effect of protein of interest (POI) ligands, linker, and E3 ligands on PROTAC degradation activity is also discussed in detail. Other novel technologies based on UPP and lysosome pathway have been discussed in this paper such as in-cell click-formed proteolysis-targeting chimeras (CLIPTACs), molecular glues, Antibody-PROTACs (Ab-PROTACs), autophagy-targeting chimeras, and lysosome-targeting chimeras. Based on the introduction of these degradation technologies, we can clearly understand the action process and degradation mechanism of these approaches. From this perspective, it will be convenient to obtain the development status of these drugs, choose appropriate degradation methods to achieve better disease treatment and provide basis for future research and simultaneously distinguish the direction of future research efforts.

Selective Protein Degradation through Tetrazine Ligation of Genetically Incorporated Unnatural Amino Acids

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Protein degradation by small tag artificial bacterial E3 ligase

Investigating Protein Degradability through Site-Specific Ubiquitin Ligase Recruitment

Identification of New Degrons in Streptococcus Mutans Reveals a Novel Strategy for Engineering Targeted, Controllable Proteolysis.

Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation Miniperspective

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development

An in-cell approach to evaluate E3 ligases for use in targeted protein degradation.

Chemically Induced Degradation of Native Proteins by Direct Recruitment to the 26S Proteasome

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Targeted Degradation of DNA/RNA Binding Proteins Via Covalent Hydrophobic Tagging

Precise Modulation of Protein Degradation by Smart PROTACs

Targeted Kinase Degradation via the KLHDC2 Ubiquitin E3 Ligase

Targeted protein degradation: expanding the toolbox

Induced degradation of SNAP-fusion proteins

Bivalent Ligands for Protein Degradation in Drug Discovery

Continuous evolution of compact protein degradation tags regulated by selective molecular glues

Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs

Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution

Recent advances in targeted protein degraders as potential therapeutic agents